logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

SABCS 2019 – Tucatinib yields PFS benefit in HER2+ breast cancer with brain metastases

OS in phase 2 HER2CLIMB was 4.5 months longer vs placebo.